ReviewFrontiers in immunology2026
Macrophage reprogramming through scavenger receptor-guided and cathepsin B-triggered nanodelivery: from intracellular mechanisms to translational applications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages are highly plastic innate immune cells. Their functional states are dynamically shaped by inflammatory signals, metabolic stress, and disease-associated remodeling. In cancer and atherosclerosis, pathological macrophages contribute to immune suppression, plaque destabilization, and therapeutic resistance, making their reprogramming a critical translational goal. Recent advances in nanomedicine provide new opportunities to manipulate macrophage behavior by combining selective cellular entry with conditionally controlled intracellular release. This review focuses on scavenger receptor-guided and cathepsin B-triggered nanodelivery systems as a mechanism-aligned strategy for phenotypic remodeling. While scavenger receptors provide selective molecular gateways enriched in diseased macrophage populations, cathepsin B serves as an endogenous trigger for subsequent nanocarrier disassembly and payload release. We discuss how aligning targeted internalization and enzymatic release can reshape macrophage function. We also examine how these platforms engage intracellular vulnerability networks, highlighting signal transducer and activator of transcription 3 (STAT3) as a translationally relevant node that stabilizes pathological states rather than an exclusive mechanistic axis. Finally, we assess major translational challenges, including off-target sequestration, target heterogeneity, and functional bioavailability. This review aims to advance the translational development of macrophage-centered immunomodulatory therapies by linking nanodelivery design to macrophage biology and disease-relevant intracellular mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.